Search Results - "Rueschoff, J."

Improved Tissue Processing in Esophageal Adenocarcinoma After Ivor Lewis Esophagectomy Allows Histological Analysis of All Surgically Removed Lymph Nodes with Significant Effects on Nodal UICC Stages by Quaas, A., Schloesser, H., Fuchs, H., Zander, T., Arolt, C., Scheel, A. H., Rueschoff, J., Bruns, C., Buettner, R., Schroeder, W.

“…Background In esophageal carcinoma, the numbers of metastatic and total removed lymph nodes (LN) are well-established variables of long-term prognosis. The…”
Get full text

Improving the turnaround time of molecular profiling for advanced non-small cell lung cancer: Outcome of a new algorithm integrating multiple approaches by Treichler, G., Hoeller, S., Rueschoff, J.H., Rechsteiner, M., Britschgi, C., Arnold, F., Zoche, M., Hiltbrunner, S., Moch, H., Akhoundova, D., Opitz, I., Curioni-Fontecedro, A.

“…Molecular tumor profiling to identify oncogenic drivers and actionable mutations has a profound impact on how lung cancer is treated. Especially in the…”
Get full text

SUPT6H controls estrogen receptor activity and cellular differentiation by multiple epigenomic mechanisms by Bedi, U, Scheel, A H, Hennion, M, Begus-Nahrmann, Y, Rüschoff, J, Johnsen, S A

“…The estrogen receptor alpha (ERα) is the central transcriptional regulator of ductal mammary epithelial lineage specification and is an important prognostic…”
Get full text

HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer by Schulz, R, Streller, F, Scheel, A H, Rüschoff, J, Reinert, M-C, Dobbelstein, M, Marchenko, N D, Moll, U M

“…Overexpression of the human epidermal growth factor receptor-2 (HER2) in breast cancer strongly correlates with aggressive tumors and poor prognosis. Recently,…”
Get full text

Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy by Hofmann, M, Stoss, O, Gaiser, T, Kneitz, H, Heinmöller, P, Gutjahr, T, Kaufmann, M, Henkel, T, Rüschoff, J

“…To investigate the correlation between centrally assessed human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) and fluorescence in situ…”
Get more information

Human epidermal growth factor receptor 2 overexpression and amplification in endoscopic biopsies and resection specimens in esophageal and junctional adenocarcinoma by van Hagen, P., Biermann, K., Boers, J. E., Stoss, O., Sleddens, H. F., van Lanschot, J. J. B., Dinjens, W. N. M., Rueschoff, J., Wijnhoven, B. P. L.

“…Summary Human epidermal growth factor receptor 2 (HER2) is overexpressed in a subset of esophageal adenocarcinomas. Frequently, biopsy material is used for…”
Get full text

Assessment of a HER2 scoring system for gastric cancer: results from a validation study by Hofmann, M, Stoss, O, Shi, D, Büttner, R, Van De Vijver, M, Kim, W, Ochiai, A, Rüschoff, J, Henkel, T

“…Aims:  Human epidermal growth factor receptor 2 (HER2) overexpression/amplification is implicated in the development of various solid tumour types. Validated…”
Get full text

6511 Human epidermal growth factor receptor 2 (HER2) in gastric cancer (GC): results of the ToGA trial screening programme and recommendations for HER2 testing by Chung, H, Bang, Y.J, Xu, J.M, Lordick, F, Sawaki, A, Lipatov, O, Lehle, M, Pickl, M, Rueschoff, J, Van Cutsem, E

Get full text

Where is the optimum cut-off value for selection of Her2 3+ cases? by Hofmann, M., Gaiser, T., Heinmoeller, P., Henkel, T., Rueschoff, J.

Get full text

Quality assurance trials for Ki67 assessment in pathology by Raap, M., Ließem, S., Rüschoff, J., Fisseler-Eckhoff, A., Reiner, A., Dirnhofer, S., von Wasielewski, R., Kreipe, H.

“…Ki67 is a broadly used proliferation marker in surgical pathology with an obvious need for standardization to improve reproducibility of assessment. Here, we…”
Get full text

Emerging technologies for assessing HER2 amplification by Penault-Llorca, Frédérique, Bilous, Michael, Dowsett, Mitch, Hanna, Wedad, Osamura, Robert Yoshiyuki, Rüschoff, Josef, van de Vijver, Marc

“…Patients with human epidermal growth factor receptor-2 (HER2)+ breast cancer are eligible for trastuzumab treatment; therefore, accurate assessment of HER2…”
Get full text

EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer by Varella-Garcia, M, Diebold, J, Eberhard, D A, Geenen, K, Hirschmann, A, Kockx, M, Nagelmeier, I, Rüschoff, J, Schmitt, M, Arbogast, S, Cappuzzo, F

“…There is a need for predictive biomarkers that identify non-small-cell lung cancer (NSCLC) patients most likely to respond to epidermal growth factor receptor…”
Get more information

Discrepancies between medical oncologists and surgeons in assessment of resectability and indication for chemotherapy in patients with colorectal liver metastases by Homayounfar, K., Bleckmann, A., Helms, H.-J., Lordick, F., Rüschoff, J., Conradi, L.-C., Sprenger, T., Ghadimi, M., Liersch, T.

“…Background Multidisciplinary discussion of the treatment of patients with colorectal liver metastases (CRLM) is advocated currently. The aim of this study was…”
Get full text

HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab by Zabaglo, L., Stoss, O., Rüschoff, J., Zielinski, D., Salter, J., Arfi, M., Bradbury, I., Dafni, U., Piccart-Gebhart, M., Procter, M., Dowsett, M.

“…Trastuzumab treatment improves survival of HER2-positive primary breast cancer. HER2 staining intensity varies widely in HER2-positive tumours. We investigated…”
Get full text

HER-2 amplification is highly homogenous in gastric cancer by Bilous, Michael, Osamura, Robert Y, Rüschoff, J, van de Vijver, Marc, Hanna, Wedad, Penault-Llorca, Frederique, Roche, Patrick

“…[...]of the ToGA trial of targeted therapy with trastuzumab, it is expected that HER2 testing is likely to become routine in all cases of gastric cancer…”
Get full text

Human epidermal growth factor receptor 2 overexpression and amplification in endoscopic biopsies and resection specimens in esophageal and junctional adenocarcinoma: HER2 expression in esophageal cancer by van Hagen, P., Biermann, K., Boers, J. E., Stoss, O., Sleddens, H. F., van Lanschot, J. J. B., Dinjens, W. N. M., Rueschoff, J., Wijnhoven, B. P. L.

Get full text

Expression of IGF-I, IGF-II, and IGF-IR in gallbladder carcinoma. A systematic analysis including primary and corresponding metastatic tumours by Kornprat, P, Rehak, P, Rüschoff, J, Langner, C

“…Aims: The insulin-like growth factor (IGF) system has been implicated in tumour development and progression. This study was designed to analyse the expression…”
Get full text

Abstract PD10-01: Impact of HER2 Staining Intensity on Prognosis and Treatment Benefit of Adjuvant Trastuzumab Given after Chemotherapy: the HERA Trial Experience by Zabaglo, L, Stoss, O, Rueschoff, J, Zielinski, D, Salter, J, Bradbury, I, Arfi, M, Dafni, O, Procter, M, Dowsett, M

“…Abstract Background: HER2 positivity is most frequently assessed by a combination of immunohistochemical (IHC) and in situ hybridization (ISH) testing. We…”
Get full text

Frequent microsatellite instability in sporadic tumors of the upper urinary tract by HARTMANN, Arndt, ZANARDO, Livia, RUESCHOFF, Josef, HOFSTAEDTER, Ferdinand, FISHEL, Richard, BOCKER-EDMONSTON, Tina, BLASZYK, Hagen, DIETMAIER, Wolfgang, STOEHR, Robert, CHEVILLE, John C, JUNKER, Kerstin, WIELAND, Wolf, KNUECHEL, Ruth

“…Urothelial carcinoma of the renal pelvis and ureter may develop sporadically or as a manifestation of hereditary nonpolyposis colorectal cancer. The majority…”
Get full text

HER2 testing in gastric cancer - results of a German expert meeting by Lordick, F, Al-Batran, S E, Hofheinz, R D, Lorenzen, S, Thuss-Patience, P, Baretton, G B, Dietel, M, Gaiser, T, Kirchner, T, Kreipe, H H, Quaas, A, Röcken, C, Rüschoff, J, Tannapfel, A

“…Valid HER2 testing is essential for optimal therapy of patients with HER2 positive gastric cancer and the correct use of first-line treatment. While each…”
Get more information